AVITA Medical Inc., a therapeutic acute wound care company listed on NASDAQ (RCEL) and ASX (AVH), announced its participation in the Canaccord Genuity 46th Annual Growth Conference. The event will take place in Boston from August 11–13, 2026. This appearance provides investors with an opportunity to engage directly with management regarding the company’s strategic direction and clinical portfolio, which includes FDA-approved RECELL technology for thermal burn and trauma wounds.

Conference Details

President and CEO Cary Vance will deliver a presentation on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time. The session aims to update stakeholders on AVITA Medical’s progress in delivering transformative solutions for acute wound care. Investors attending the conference may request one-on-one meetings with AVITA Medical representatives through their Canaccord Genuity sales representative.

Webcast Access

For investors unable to attend in person, AVITA Medical will provide a live webcast of the presentation. A replay of the session will also be available under the Investor Relations Events & Presentations section of the company’s website at https://ir.avitamedical.com/events-and-presentations .

About AVITA Medical

AVITA Medical specializes in technologies designed to optimize wound healing and accelerate patient recovery. Its flagship product, RECELL, is approved by the FDA for treating thermal burn and trauma wounds by harnessing the healing properties of a patient’s own skin to create Spray-On Skin. The company holds exclusive rights in the U.S. to market Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Internationally, RECELL is CE-marked in Europe, TGA-certified in Australia, listed with Medsafe in New Zealand, and PMDA-approved in Japan.

Contact Information

Investor inquiries should be directed to Ben Atkins at +1-805 341 1571 or investor@avitamedical.com . Media inquiries can be sent to media@avitamedical.com . The release was authorized by the Chief Financial Officer of AVITA Medical Inc.

AVITA Medical will report its second quarter 2026 financial results after the close of the U.S. financial markets on August 6, 2026. The company will host a conference call and webcast at 1:30 p.m. Pacific Time to discuss its financial performance and recent business highlights. The announcement provides investors with an opportunity to review the company's progress in the acute wound care sector.

Conference Call Details

To participate in the live earnings conference call, investors must register in advance to receive dial-in details and a personal PIN. The webcast will be available for listening via a provided link. For those unable to attend the live broadcast, a replay will be accessible on the Events page of the company’s investor relations website.

Key Dates and Times

About AVITA Medical

AVITA Medical is a therapeutic acute wound care company delivering solutions designed to optimize wound healing and accelerate patient recovery. Its flagship technology, RECELL, is FDA-approved for treating thermal burn and trauma wounds. The company holds exclusive rights to market Cohealyx and PermeaDerm in the U.S. In international markets, RECELL and RECELL GO are CE-marked in Europe, TGA-certified in Australia, listed with Medsafe in New Zealand, and PMDA-approved in Japan.